The European Medicines Agency (EMA) said it expects to launch the next phase of its business continuity plan on October 1, 2018 at the latest. The plan will allow the agency to safeguard core activities related to the evaluation and supervision of medicines, while it has to intensify its preparations for the physical move to Amsterdam…
EMA Review Of Zinbryta: Risks Outweigh Benefits
EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has confirmed that the multiple sclerosis medicine Zinbryta (daclizumab beta) poses a risk of serious and potentially fatal immune reactions affecting the brain, liver and other organs. Patients could be at risk from the start of treatment and for several months after stopping treatment, and it is not possible to predict…
European Medicines Agency To Relocate To Amsterdam From London
The European Medicines Agency (EMA) will relocate to Amsterdam in the Netherlands. This decision was taken November 20 by the EU’s 27 member states in the margins of the General Affairs Council (Article 50). The Agency now has just over 16 months to prepare for the move and take up its operations in Amsterdam on March 30,…